The consumption of an adequate quantity of protein in the diet is essential to maintain a healthy body composition and functioning. It is also well established that all proteins are not equal regarding their ability to promote health benefits. Recently, we have innovated in that matter by showing that under the context of high intake of dietary fat, the dairy protein casein was more effective than a mix of proteins representative of a western diet to prevent body weight gain and insulin resistance. This was explained in part by modifications of the gut microbiota. This finding represents the main conceptual basis of the present research program that is aimed to determine the impact of dairy protein from yogurt compared to a plant-based equivalent on body composition indicators including muscle mass and bone mineral density, in relation to the profile of the gut microbiota, the production of newly discovered protein-derived metabolites, and markers of metabolic health. This program will include a human and an animal component requiring the testing of these variables before and after a standardized intervention. The human component will be a clinical study consisting of a 12-week diet-based weight loss intervention in postmenopausal overweight women being randomly assigned to one of the three following groups: yogurt, plant-based yogurt, or kept on diet without supplements. The animal experimentation will permit to causally determine the implication of the gut microbiota in the protein effects following transfer of the human bacteria to germ free mice and validate the benefits seen in humans. It is anticipated that these two complementary investigative approaches will allow a thorough documentation of the impact of fermented dairy protein on body composition and functioning, a better understanding of the underlying mechanisms, and the identification of new biomarkers to better appreciate related health benefits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
75
Dairy yogurt: two serving daily
Plant based yogurt: two servings daily
No yogurt: zero serving yogurt
INAF, Université Laval
Québec, Quebec, Canada
RECRUITINGChange in bone health
Assessment of bone mineral density using Dual X-ray Absorptiometry scan
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in bone health
Assessment of bone turnover biomarkers (osteocalcin, c-telopeptide, Amino terminal propeptide of type 1 procollagen) (all in ng\\mL)
Time frame: At baseline and at the end of the intrevention (12 weeks)
Change in gut microbiota
Assessment of global variation of the fecal microbiota
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in gut microbiota function
Assessment of short-chain fatty acid (SCFA) in feces
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in body weight
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in anthropometric measures
Assessment of body mass index (BMI) using weight and height. These two measurements will be combined to calculate BMI in kg/m2
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in anthropometric measure
Assessment of waist circumference
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in body composition
Assessment of changes in lean mass, fat mass and visceral fat mass (all in grams) using body composition by Dual X-ray Absorptiometry scan
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in skeletal muscle health
muscle strength using handgrip strength tool (kg)
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in skeletal muscle health
Assessment of physical performance using Timed Up and go Test
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in skeletal muscle health
Assessment of functionnal capicity using 6-minute walk test)
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in Resting Metabolic Rate (RMR)
Change in RMR using Calorimetry Device
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in Appetite and Satiety
Assessment of leptin and ghrelin (both with same units of measurement)
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in Appetite and Satiety
Assessment of appetite and satiety using visual analog scale
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in Eating behaviors
Assessment of eating behaviors using Food Cravings Questionnaire (FCQ-T)
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in glycemia
Assessment of fasting glucose concentration
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in insulinemia
Assessment of fasting insulin concentration
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in lipid profile
Assessment of triglycerides, LDL-cholesterol and HDL-cholesterol
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in blood pressure
Assessment of systolic and diastolic blood pressure
Time frame: At baseline and at the end of the intervention (12 weeks)
Change in chronic inflammation
Assessment of plasma high sensitive C-Reactive Protein (hs-CRP) concentrations
Time frame: At baseline and at the end of the intervention (12 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.